Assembly Bio reports Phase 1b data: ABI-1179 98% HSV-2 shedding reduction, ABI-5366 monthly 76%

ASSEMBLY BIOSCIENCES, INC.

ABI-1179 50 mg weekly: 98% HSV-2 shedding reduction (p<0.01), exceeds 80-85% target; 91% lesion reduction (p<0.01).
ABI-1179: >99% reduction in high viral load shedding, a transmission surrogate.
ABI-5366 monthly dose: 76% HSV-2 shedding reduction (p<0.01), 88% lesion reduction (p=0.01), 81% high viral load reduction.
ABI-5366 weekly 350 mg confirmed: 94% shedding, 97% lesion reduction vs placebo.
Both candidates well-tolerated; Phase 2 planning for ABI-1179 and ABI-5366 weekly; monthly optimization ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.